Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients - Archive ouverte HAL Access content directly
Journal Articles Nature Communications Year : 2020

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (7) , (7) , (7) , (7) , (8) , (8) , (8) , (9) , (9) , (10) , (11)
1
2
3
4
5
6
7
8
9
10
11

Abstract

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.
Fichier principal
Vignette du fichier
s41467-020-17907-w.pdf (527.59 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

inserm-02964247 , version 1 (12-10-2020)

Identifiers

Cite

Simon G P Funnell, William E Dowling, César Muñoz-Fontela, Pierre-Stéphane Gsell, Donald E Ingber, et al.. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nature Communications, 2020, 11 (1), pp.4253. ⟨10.1038/s41467-020-17907-w⟩. ⟨inserm-02964247⟩
74 View
97 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More